Understanding and Rescuing the Splicing Defect Caused by the Frequent ABCA4 Variant c.4253+43G>A Underlying Stargardt Disease.

IF 4 2区 医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY
Nucleic acid therapeutics Pub Date : 2024-04-01 Epub Date: 2024-03-12 DOI:10.1089/nat.2023.0076
Nuria Suárez-Herrera, Alejandro Garanto, Rob W J Collin
{"title":"Understanding and Rescuing the Splicing Defect Caused by the Frequent <i>ABCA4</i> Variant c.4253+43G>A Underlying Stargardt Disease.","authors":"Nuria Suárez-Herrera, Alejandro Garanto, Rob W J Collin","doi":"10.1089/nat.2023.0076","DOIUrl":null,"url":null,"abstract":"<p><p>Pathogenic variants in <i>ABCA4</i> are the underlying molecular cause of Stargardt disease (STGD1), an autosomal recessive macular dystrophy characterized by a progressive loss of central vision. Among intronic <i>ABCA4</i> variants, c.4253+43G>A is frequently detected in STGD1 cases and is classified as a hypomorphic allele, generally associated with late-onset cases. This variant was previously reported to alter splicing regulatory sequences, but the splicing outcome is not fully understood yet. In this study, we attempted to better understand its effect on splicing and to rescue the aberrant splicing via antisense oligonucleotides (AONs). Wild-type and c.4253+43G>A variant-harboring maxigene vectors revealed additional skipping events, which were not previously detected upon transfection in HEK293T cells. To restore exon inclusion, we designed a set of 27 AONs targeting either splicing silencer motifs or the variant region and screened these in maxigene-transfected HEK293T cells. Candidate AONs able to promote exon inclusion were selected for further testing in patient-derived photoreceptor precursor cells. Surprisingly, no robust splicing modulation was observed in this model system. Overall, this research helped to adequately characterize the splicing alteration caused by the c.4253+43G>A variant, although future development of AON-mediated exon inclusion therapy for <i>ABCA4</i> is needed.</p>","PeriodicalId":19412,"journal":{"name":"Nucleic acid therapeutics","volume":" ","pages":"73-82"},"PeriodicalIF":4.0000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nucleic acid therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/nat.2023.0076","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/12 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Pathogenic variants in ABCA4 are the underlying molecular cause of Stargardt disease (STGD1), an autosomal recessive macular dystrophy characterized by a progressive loss of central vision. Among intronic ABCA4 variants, c.4253+43G>A is frequently detected in STGD1 cases and is classified as a hypomorphic allele, generally associated with late-onset cases. This variant was previously reported to alter splicing regulatory sequences, but the splicing outcome is not fully understood yet. In this study, we attempted to better understand its effect on splicing and to rescue the aberrant splicing via antisense oligonucleotides (AONs). Wild-type and c.4253+43G>A variant-harboring maxigene vectors revealed additional skipping events, which were not previously detected upon transfection in HEK293T cells. To restore exon inclusion, we designed a set of 27 AONs targeting either splicing silencer motifs or the variant region and screened these in maxigene-transfected HEK293T cells. Candidate AONs able to promote exon inclusion were selected for further testing in patient-derived photoreceptor precursor cells. Surprisingly, no robust splicing modulation was observed in this model system. Overall, this research helped to adequately characterize the splicing alteration caused by the c.4253+43G>A variant, although future development of AON-mediated exon inclusion therapy for ABCA4 is needed.

了解并挽救由频发 ABCA4 变异 c.4253+43G>A 导致的剪接缺陷,它是斯塔加特病的基础。
ABCA4的致病变体是Stargardt病(STGD1)的分子病因,STGD1是一种常染色体隐性黄斑营养不良症,其特征是中心视力进行性丧失。在内含子 ABCA4 变异中,c.4253+43G>A 经常在 STGD1 病例中被检测到,并被归类为低等位基因,通常与晚发病例有关。以前曾有报道称该变异改变了剪接调控序列,但其剪接结果尚不完全清楚。在本研究中,我们试图更好地了解它对剪接的影响,并通过反义寡核苷酸(AONs)来挽救异常剪接。野生型和c.4253+43G>A变体携带的maxigene载体发现了额外的跳过事件,这是以前转染HEK293T细胞时未检测到的。为了恢复外显子包含,我们设计了一组 27 个以剪接沉默子基序或变异区为目标的 AONs,并在转染了 maxigene 的 HEK293T 细胞中对这些 AONs 进行了筛选。筛选出能够促进外显子包含的候选 AONs,并在源自患者的感光前体细胞中进行进一步测试。令人惊讶的是,在这个模型系统中没有观察到强大的剪接调节作用。总之,这项研究有助于充分描述由c.4253+43G>A变异引起的剪接改变,但未来还需要开发AON介导的ABCA4外显子包含疗法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Nucleic acid therapeutics
Nucleic acid therapeutics BIOCHEMISTRY & MOLECULAR BIOLOGY-CHEMISTRY, MEDICINAL
CiteScore
7.60
自引率
7.50%
发文量
47
审稿时长
>12 weeks
期刊介绍: Nucleic Acid Therapeutics is the leading journal in its field focusing on cutting-edge basic research, therapeutic applications, and drug development using nucleic acids or related compounds to alter gene expression. The Journal examines many new approaches for using nucleic acids as therapeutic agents or in modifying nucleic acids for therapeutic purposes including: oligonucleotides, gene modification, aptamers, RNA nanoparticles, and ribozymes.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信